ArticleOncotarget2016
SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 29 citations in OpenAlex.
- CEACAM1 Is Associated With an Immune-Activated Tumor Microenvironment and Therapeutic Stratification in Sarcoma.International journal of genomics · 2026Article
- SOX9 drives KRAS-induced lung adenocarcinoma progression and suppresses anti-tumor immunity.Oncogene · 2023Article
- New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy.Seminars in cancer biology · 2023Review
- Comprehensive analysis, immune, and cordycepin regulation for SOX9 expression in pan-cancers and the matched healthy tissues.Frontiers in immunology · 2023Article
- CEACAM1 is a direct SOX10 target and inhibits melanoma immune infiltration and stemness.iScience · 2022Article
- A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma.Neuro-oncology · 2022Article
- SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects.Cell reports · 2021Article
- A Dynamic Transcription Factor Signature Along the Colorectal Adenoma-Carcinoma Sequence in Patients With Co-Occurrent Adenoma and Carcinoma.Frontiers in oncology · 2021Article
- Article
- High expression of carcinoembryonic antigen-associated cell adhesion molecule 1 is associated with microangiogenesis in esophageal squamous cell carcinoma.Translational cancer research · 2020Article
- The expression of SOX9, Tiam1, and PTEN is correlated with angiogenesis and prognosis in gastric cancer.Translational cancer research · 2020Article
- Cell-dependent regulation of vasculogenic mimicry by carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1).Biochemistry and biophysics reports · 2020Article
- PPARγ inhibition boosts efficacy of PD-L1 Checkpoint Blockade Immunotherapy against Murine Melanoma in a sexually dimorphic manner.International journal of biological sciences · 2020Article
- A Sox2-Sox9 signalling axis maintains human breast luminal progenitor and breast cancer stem cells.Oncogene · 2019Article
- SOX9 is a dose-dependent metastatic fate determinant in melanoma.Journal of experimental & clinical cancer research : CR · 2019Article
- miR-1-3p suppresses proliferation of hepatocellular carcinoma through targeting SOX9.OncoTargets and therapy · 2019Article
- Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells.Neoplasia (New York, N.Y.) · 2018Article
- Abnormal expression of circulating and tumor-infiltrating carcinoembryonic antigen-related cell adhesion molecule 1 in patients with glioma.Oncology letters · 2018Article
- Abl and Arg mediate cysteine cathepsin secretion to facilitate melanoma invasion and metastasis.Science signaling · 2018Article
- SOX9/miR-130a/CTR1 axis modulates DDP-resistance of cervical cancer cell.Cell cycle (Georgetown, Tex.) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As melanoma cells are immunogenic, they instigate an adaptive immune response and production of anti-tumor T-cells. A central factor in this interaction is CEACAM1 (carcinoembryonic antigen cell adhesion molecule 1), a transmembrane glycoprotein previously shown in our lab to protect melanoma cells from T cell-mediated killing. In this study, we examine the role of transcription factor SOX9 in the regulation of CEACAM1 expression and immune resistance in melanoma cells. Knockdown of endogenous SOX9 results in CEACAM1 up-regulation, while its overexpression leads to the opposite effect. We show that SOX9 controls CEACAM1 expression at a transcriptional level, but in an indirect manner, as regulation of the CEACAM1 promoter remains intact even when all eight potential SOX9-binding sites are abolished. A series of promoter truncations localizes the SOX9-controlled area to the proximal 200bp of the promoter. Point mutations in putative Sp1 and ETS1 binding sites identify these transcription factors as the primary SOX9-controlled mediators. Co-immunoprecipitation studies show that SOX9 and Sp1 physically interact in melanoma cells, while silencing of SOX9 down-regulates ETS1, but not Sp1, in the same cells. Finally, knockdown of SOX9 indeed renders melanoma cells resistant to T cell-mediated killing, in line with the increased CEACAM1 expression. In conclusion, we show that SOX9 regulates CEACAM1 expression in melanoma cells, and thereby their immune resistance. As CEACAM1 is a pivotal protein in melanoma biology and immune crosstalk, further understanding of its regulation can provide new insights and contribute to the development of novel approaches to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.